PMID- 23152229
OWN - NLM
STAT- MEDLINE
DCOM- 20130115
LR  - 20200511
IS  - 1469-493X (Electronic)
IS  - 1361-6137 (Linking)
VI  - 11
DP  - 2012 Nov 14
TI  - Shengmai (a traditional Chinese herbal medicine) for heart failure.
PG  - CD005052
LID - 10.1002/14651858.CD005052.pub4 [doi]
AB  - BACKGROUND: This systemic review is an update of a review previously published in 
      2011. Heart failure is a major public health problem worldwide. Shengmai (a 
      traditional Chinese herbal medicine) has long been used as a complementary 
      treatment for heart failure in China. OBJECTIVES: To assess the effects (both 
      benefits and harms) of Shengmai for heart failure. SEARCH METHODS: We searched 
      CENTRAL and DARE on The Cochrane Library (2011, Issue 1), MEDLINE (1948 to March 
      2011), EMBASE (1980 to March 2011), AMED (1985 to August 2008) (AMED was not 
      searched for the update as it is no longer available to the person conducting the 
      searches), BIOSIS (1969 to March 2011), CBM (1978 to April 2011), VIP (1989 to 
      April 2011) and CNKI (1979 to April 2011). We also handsearched Chinese journals. 
      No language restrictions were applied. SELECTION CRITERIA: Randomized controlled 
      trials (RCTs) of Shengmai plus usual treatment versus usual treatment alone or 
      Shengmai versus placebo in treating heart failure, irrespective of blinding 
      status, were included. More stringent inclusion criteria were applied in this 
      update and only studies with a clear description of randomization methods and 
      classified as true RCTs were included. DATA COLLECTION AND ANALYSIS: Two authors 
      independently selected trials, assessed methodological quality and extracted 
      data. Dichotomous and continuous data were calculated as relative risk (RR) and 
      mean difference (MD) or standardized mean difference (SMD), respectively. A 
      random-effects model and fixed-effect model were used to perform meta-analysis 
      with and without heterogeneity, respectively. MAIN RESULTS: Nine RCTs (600 
      patients) with seven comparing Shengmai plus usual treatment with usual treatment 
      alone and three comparing Shengmai with placebo (one RCT contained three arms) 
      were included in this updated review. Based upon the seven RCTs (494 patients), 
      improvement of the New York Heart Association (NYHA) functional classification 
      was more common in patients taking Shengmai plus usual treatment than in those 
      receiving usual treatment alone (risk ratio 0.33, 95% confidence interval 0.23 to 
      0.47). Beneficial effects of Shengmai in treating heart failure were also 
      observed on other outcomes, including an exercise test, ejection fraction, 
      cardiac output, cardiac index and left ventricular end-systolic volume. The three 
      RCTs (106 patients) which compared Shengmai with placebo reported an improvement 
      in NYHA functional classification, ejection fraction, stroke volume, cardiac 
      index and myocardial contractility. Three out of the nine RCTs reported mild 
      adverse effects, and two patients were withdrawn due to the adverse effects. The 
      results of this review should be interpreted with caution. This is due to the 
      studies being of low quality, their small sample size, and the significant 
      heterogeneity for certain outcomes including ejection fraction and cardiac 
      output. AUTHORS' CONCLUSIONS: Shengmai may be beneficial in treating heart 
      failure, especially in terms of improving the NYHA functional classification with 
      Shengmai plus usual treatment. However, the evidence for its effects on mortality 
      and hospitalisation are not available yet. Therefore more studies, of higher 
      quality and long-term follow-up, are needed to provide more evidence for the 
      future use of Shengmai.
FAU - Chen, Jie
AU  - Chen J
AD  - Department of Evidence-Based Medicine and Clinical Epidemiology, West China 
      Hospital, Sichuan University, Chengdu, China. ebm_chenjin@126.com
FAU - Yao, Yu
AU  - Yao Y
FAU - Chen, Haining
AU  - Chen H
FAU - Kwong, Joey S W
AU  - Kwong JS
FAU - Chen, Jin
AU  - Chen J
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20121114
PL  - England
TA  - Cochrane Database Syst Rev
JT  - The Cochrane database of systematic reviews
JID - 100909747
RN  - 0 (Cardiotonic Agents)
RN  - 0 (Drug Combinations)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (fructus schizandrae, radix ginseng, radix ophiopogonis drug combination)
SB  - IM
UOF - Cochrane Database Syst Rev. 2011;(2):CD005052. PMID: 21328272
UIN - Cochrane Database Syst Rev. 2014;4:CD005052. PMID: 24733159
MH  - Cardiotonic Agents/*therapeutic use
MH  - Drug Combinations
MH  - Drugs, Chinese Herbal/*therapeutic use
MH  - Heart Failure/*drug therapy
MH  - Humans
MH  - Phytotherapy/*methods
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
EDAT- 2012/11/16 06:00
MHDA- 2013/01/16 06:00
CRDT- 2012/11/16 06:00
PHST- 2012/11/16 06:00 [entrez]
PHST- 2012/11/16 06:00 [pubmed]
PHST- 2013/01/16 06:00 [medline]
AID - 10.1002/14651858.CD005052.pub4 [doi]
PST - epublish
SO  - Cochrane Database Syst Rev. 2012 Nov 14;11:CD005052. doi: 
      10.1002/14651858.CD005052.pub4.